Eugia Unit III FDA observations and production halt
FDA issued Form 483 with 9 observations at Eugia Unit III; manufacturing paused, expected $20M revenue impact in Q4. Risk of prolonged shutdown and market share loss.
AUROPHARMA / Q3-FY24 / risks
Keep the risk register visible.
Aurobindo Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Potential market share loss in injectable products
Analyst raised concern about losing market share in key products from Eugia Unit III; management acknowledged risk but expects to recover with existing stock and phased restart.
Penicillin G plant pricing risk
Analyst questioned profitability if Pen G prices fall below $20/kg; management deferred response, indicating uncertainty.
Biosimilar commercialization delays
Pneumococcal vaccine missed national tender timeline; management indicated no near-term market entry, highlighting execution risk in biosimilar launches.